Australian Meningococcal Surveillance Programme Annual Report, 2021
DOI:
https://doi.org/10.33321/cdi.2022.46.46Keywords:
antimicrobial resistance, disease surveillance, invasive meningococcal disease, Neisseria meningitidisAbstract
Invasive meningococcal disease (IMD) is a notifiable disease in Australia, with both probable and laboratory-confirmed cases of IMD reportable to the National Notifiable Diseases Surveillance System (NNDSS). In 2021, there were 74 notifications of IMD made, the lowest number recorded since 1991 when records began. Ninety-one percent of notified cases (67/74) were laboratory confirmed, with 69% of laboratory-confirmed cases (46/67) diagnosed by bacterial culture and 31% (21/67) by nucleic acid amplification testing. The serogroup was determined for 63/67 laboratory-confirmed cases (94%): serogroup B (MenB) accounted for 52% of infections (35/67); MenW for 22% (15/67); MenY for 19% (13/67); there were no infections attributed to MenC. Fine typing was available on 37/67 (55%) where the serogroup was determined. The greatest variability was in MenB, with nine different porA types represented. All MenW infections belonged to a single porA type (P1.5,2) with five different MLST sequence types represented: 11, 574, 1287, 12351, 13135; all belonged to clonal complex 11, the hypervirulent strain reported in recent outbreaks in Australia and overseas. All MenY were from the same porA antigen type, P1.5-1,10-1: MLST sequence type 1655; clonal complex 23.
Peaks occurred in children less than 5 years, reaching 24% (16/67) of reported cases, and in those aged 15–19 years reaching 16% (11/67) of reported cases. It is notable that 15% (10/67) of notifications were in persons aged 45–64 years, and an equivalent proportion (15%; 10/67) in adults aged 65 years and above. MenB infections predominated in persons aged 15–19 years (100%, 11/11), and comprised 56% (9/16) of infections in children aged less than 5 years. By contrast, Men W infections accounted for half (5/10) of IMD detections in infants less than 1 year, and 30% (3/10) of infections in persons aged 45–65 years. MenY infections predominated in adults aged 65 years and greater, resulting in 70% (7/10) of IMD in this age group.
All 46 IMD isolates had antimicrobial susceptibility testing performed. Minimum inhibitory concentration (MIC) values were categorised using Clinical Laboratory Standards Institute (CLSI) interpretative criteria: 13% (6/46) were defined as penicillin resistant (MIC value, ≥ 0.5 mg/L); 59% (27/46) had intermediate susceptibility to penicillin (MIC values, 0.125 and 0.25 mg/L) and 28% (13/46) were susceptible to penicillin. All isolates were susceptible to ceftriaxone and rifampicin. A single MenB IMD isolate from New South Wales exhibited ciprofloxacin resistance (MIC value, 0.125 mg/L).
Downloads
References
National Neisseria Network. Meningococcal Isolate Surveillance Australia 1994. Commun Dis Intell. 1995;19(12):286–9.
Australian Government Department of Health. National Notifiable Disease Surveillance System. [Webpage.] Canberra: Australian Government Department of Health; 2021. [Accessed on 4 May 2022.] Available from: http://www9.health.gov.au/cda/source/cda-index.cfm.
National Notifiable Diseases Surveillance System (NNDSS). Number of notifications of Meningococcal disease (invasive), received from State and Territory health authorities in the period of 1991 to 2012 and year-to-date notifications for 2014–2021. Available from: http://www9.health.gov.au/cda/source/rpt_4_sel.cfm.
Australian Government Department of Health. Invasive meningococcal disease. [Internet.] Canberra: Australian Government Department of Health; 20 March 2020. Available from: https://www.health.gov.au/internet/main/publishing.nsf/Content/ohp-meningococcal-W.htm.
Communicable Diseases Network Australia (CDNA). Invasive meningococcal disease: CDNA national guidelines for public health units. Canberra: Australian Government Department of Health, CDNA; March 2017. [Accessed in April 2022.] Available from: https://www1.health.gov.au/internet/main/publishing.nsf/Content/0A31EEC4953B7E6FCA257DA3000D19DD/$File/IMD-SoNG.pdf.
George CRR, Smith HV, Lahra MM. Neisseria meningitidis. In de Filippis I, ed. Molecular Typing in Bacterial Infections, Volume I. London: Springer International Publishing, Springer Cham, 2022;85–99.
Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing. 31st ed. CLSI supplement M100. Wayne, PA: CLSI; 2021.
Tapsall JW, Shultz T, Limnios E, Munro R, Mercer J, Porritt R et al. Surveillance of antibiotic resistance in invasive isolates of Neisseria meningitidis in Australia 1994–1999. Pathology. 2001;33(3):359–61. doi: https://doi.org/10.1080/pat.33.3.359.361.
Abad R, López EL, Debbag R, Vázquez JA. Serogroup W meningococcal disease: global spread and current affect on the Southern Cone in Latin America. Epidemiol Infect. 2014;142(12):2461–70. doi: https://doi.org/10.1017/S0950268814001149.
Ladhani SN, Beebeejaun K, Lucidarme J, Campbell H, Gray S, Kaczmarski E et al. Increase in endemic Neisseria meningitidis capsular group W sequence type 11 complex associated with severe invasive disease in England and Wales. Clin Infect Dis. 2015;60(4):578–85. doi: https://doi.org/10.1093/cid/ciu881.
George CR, Booy R, Nissen MD, Lahra MM. The decline of invasive meningococcal disease and influenza in the time of COVID-19: the silver linings of the pandemic playbook. Med J Aust. 2022. doi: https://doi.org/10.5694/mja2.51463.
Chiu C, Dey A, Wang H, Menzies R, Deeks S, Mahajan D et al. Vaccine preventable diseases in Australia, 2005 to 2007. Commun Dis Intell Q Rep. 2010;34(Suppl):S1–167.
Australian Government Department of Health. Immunise Australia Program. Meningococcal Disease. [Internet.] Canberra: Australian Government Department of Health; 20 April 2015. Available from: https://www.health.gov.au/internet/immunise/publishing.nsf/Content/immunise-meningococcal.
Araya P, Fernández J, Del Canto F, Seoane M, Ibarz-Pavón AB, Barra G et al. Neisseria meningitidis ST-11 clonal complex, Chile 2012. Emerg Infect Dis. 2015;21(2):339–41. doi: https://doi.org/10.3201/eid2102.140746.
Bröker M, Jacobsson S, Kuusi M, Pace D, Simões MJ, Skoczynska A et al. Meningococcal serogroup Y emergence in Europe: update 2011. Hum Vaccin Immunother. 2012;8(12):1907–11. doi: https://doi.org/10.4161/hv.21794.
Willerton L, Lucidarme J, Walker A, Lekshmi A, Clark SA, Walsh L et al. Antibiotic resistance among invasive Neisseria meningitidis isolates in England, Wales and Northern Ireland (2010/11 to 2018/19). PLoS One. 2021;16(11):e0260677. doi: https://doi/org/10.1371/journal.pone.0260677.
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2022 Communicable Diseases Intelligence
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
